Related Experiment Video
Updated: Aug 9, 2026
Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
Published on: April 26, 2018
Gefitinib accumulation in glioblastoma tissue
Silvia Hofer1, Karl Frei, Hans Peter Rutz
1Department of Oncology, Zurich University Hospital, Zürich, Switzerland. silvia.hofer@usz.ch
Abstract:
Therapeutic agents for brain tumors confront multiple physical and metabolic hurdles. These include the blood brain barrier (BBB), vascular and interstitial barriers, clearing by MDR1 and other ABC transporter proteins, and drug catabolism. Here, we report an accumulation of gefitinib in glioblastoma (GBM) tissue to over a dozen times plasma levels, and propose that some mechanisms converge to achieve such accumulation: (1) small molecular size of gefitinib facilitates access by diffusion; (2) its high water solubility enables thermodynamic retention inside malignant cells; and (3) low CYP3A4 activity in GBM tissue, the main enzyme for gefitinib catabolism, prevents metabolic elimination. Our data confirm the capacity of gefitinib to accumulate in solid human tumors in vivo.
Insights
Gefitinib accumulates in glioblastoma (GBM) tumors, exceeding plasma levels significantly. This accumulation is attributed to its small size, solubility, and reduced metabolism within the tumor microenvironment, enhancing its potential as a brain tumor therapeutic.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Therapeutic agents face challenges reaching brain tumors, including the blood-brain barrier (BBB) and drug efflux transporters.
- Metabolic degradation by enzymes like CYP3A4 can limit drug efficacy in the tumor microenvironment.
Purpose of the Study:
- To investigate the in vivo accumulation of gefitinib in glioblastoma (GBM) tissue.
- To elucidate the mechanisms contributing to gefitinib accumulation in GBM.
Main Methods:
- Quantification of gefitinib levels in GBM tissue and plasma.
- Assessment of factors influencing drug distribution and metabolism within the tumor.
Main Results:
- Gefitinib accumulated in GBM tissue to over 12 times plasma concentrations.
- Mechanisms identified include gefitinib's small molecular size, high water solubility, and low CYP3A4 activity in GBM tissue.
Conclusions:
- Gefitinib demonstrates significant accumulation in solid human glioblastoma tumors in vivo.
- These findings support gefitinib's potential for enhanced therapeutic delivery and retention in brain tumors.
